-
Mashup Score: 1
In heavily pretreated patients with recurrent low-grade serous ovarian cancer, the combination of avutometinib plus defactinib showing promising results within the phase 2 ENGOT-ov60/GOG-3052/RAMP 201 trial.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
Patients who are heavily pretreated with #LGSOC had high response rates, regardless of the number of prior lines of therapy received, when treated with avutometinib + defactinib, according to part A of the phase 2 RAMP 201 trial. #SGO24 | @royalmarsdenNHS https://t.co/twmeUQbvtO